CaaMTech, an Issaquah, WA-based psychedelic drug discovery company, raised $22M in Series A funding.
The round was led by Noetic Fund.
The company intends to use the funds to support its cross-disciplinary science program, expand its leadership team, and advance its foremost drug development candidates into human trials.
Led by founder and CEO Dr. Andrew Chadeayne, CaaMTech is focused on engineering psychedelic drugs. Founded in 2017 to fill the unmet need for pure, well-characterized psychedelic drugs, CaaMTech has since then produced an extensive library of novel, analytically pure compounds that are nearing advancement into human trials.